Zura Bio Ltd ZURA
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.
Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis. We focus on targets for which human data, including biomarker findings, genetic associations and prior clinical studies, inform therapeutic rationale and development decisions. We seek to advance product candidates in therapeutic areas where there remains meaningful unmet medical need and where, if clinical benefit is demonstrated, there may be potential for commercial relevance.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $42.1M | $24.4M | $44.0M | $23.7M | — | — |
| SG&A | $33.2M | $30.8M | $18.6M | $3.5M | — | — |
| Total operating expenses | $75.2M | $55.2M | $62.6M | $27.2M | — | — |
| Operating income | -$75.2M | -$55.2M | -$62.6M | -$27.2M | — | — |
| Pre-tax income | -$68.7M | -$52.4M | -$60.6M | -$27.3M | — | — |
| Income tax | — | $0 | $0 | — | — | — |
| Net income | -$68.7M | -$52.4M | -$60.4M | -$25.7M | — | — |
| EPS, basic | -1.06 | -0.60 | -2.09 | -141.97 | — | — |
| EPS, diluted | -1.06 | -0.60 | -2.09 | -141.97 | — | — |
| Shares, diluted (wtd. avg.) | 94.2M | 75.1M | 33.1M | 228,148 | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $109.4M | $176.5M | $99.8M | $1.6M | $729.2K | $0 |
| Total current assets | $112.3M | $178.7M | $100.8M | $1.8M | $1.2M | — |
| Property, plant and equipment | $126.0K | $91.0K | — | — | — | — |
| Total assets | $113.9M | $179.5M | $100.8M | $5.3M | $140.6M | — |
| Accounts payable | $1.3M | $733.0K | $2.7M | $2.0M | $69.9K | — |
| Total current liabilities | $12.4M | $19.5M | $20.3M | $14.8M | $272.3K | — |
| Total liabilities | $12.4M | $19.5M | $21.3M | $14.8M | $10.4M | — |
| Retained earnings | -$224.5M | -$155.9M | -$103.5M | -$32.1M | -$9.2M | — |
| Total equity | $101.5M | $146.8M | $60.9M | -$32.1M | -$9.2M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$64.8M | -$28.1M | -$15.1M | -$1.2M | — | — |
| Depreciation and amortisation | $49.0K | $9.0K | — | — | — | — |
| Stock-based compensation | $12.3M | $16.8M | $7.5M | $334.0K | — | — |
| Capital expenditure | $113.0K | $75.0K | — | — | — | — |
| Investing cash flow | -$113.0K | -$5.1M | -$8.0M | -$12.0M | — | — |
| Financing cash flow | -$2.2M | $109.8M | $121.3M | $14.8M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-032080.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | — | -$25.7M | -$60.4M | -$52.4M | -$68.7M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |